Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
13.08 (1y: -7%)
Market Cap 668.28 M P/E(ttm)
Enterprise Value 344.07 M P/B 1.90
MNTA- NAS (USA)
Momenta Pharmaceuticals, Inc.
Not Rated
Top Ranked Predictable Companies
$13.08
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyย’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry		 vs
history
Cash to Debt No Debt
MNTA's Cash to Debt is ranked higher than
53% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. MNTA: No Debt )
MNTA' s 10-Year Cash to Debt Range
Min: 15.61   Max: No Debt
Current: No Debt
Equity to Asset 0.87
MNTA's Equity to Asset is ranked higher than
86% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 0.54 vs. MNTA: 0.87 )
MNTA' s 10-Year Equity to Asset Range
Min: -0.86   Max: 0.94
Current: 0.87
-0.86
0.94
Interest Coverage No Debt
MNTA's Interest Coverage is ranked higher than
50% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. MNTA: No Debt )
MNTA' s 10-Year Interest Coverage Range
Min: 238   Max: No Debt
Current: No Debt
F-Score: 2
Z-Score: 9.62
M-Score: -1.5
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyย’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
ย•ย•3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rankย•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry		 vs
history
Operating margin (%) -94.00
MNTA's Operating margin (%) is ranked lower than
68% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -52.55 vs. MNTA: -94.00 )
MNTA' s 10-Year Operating margin (%) Range
Min: -548.6   Max: 63.5
Current: -94
-548.6
63.5
Net-margin (%) -91.8
MNTA's Net-margin (%) is ranked lower than
69% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -55.70 vs. MNTA: -91.8 )
MNTA' s 10-Year Net-margin (%) Range
Min: -546.4   Max: 63.7
Current: -91.8
-546.4
63.7
ROE (%) -16.3
MNTA's ROE (%) is ranked higher than
54% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -16.60 vs. MNTA: -16.3 )
MNTA' s 10-Year ROE (%) Range
Min: -68   Max: 44.7
Current: -16.3
-68
44.7
ROA (%) -14.4
MNTA's ROA (%) is ranked lower than
52% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -14.40 vs. MNTA: -14.4 )
MNTA' s 10-Year ROA (%) Range
Min: -54   Max: 42.8
Current: -14.4
-54
42.8
ROC (Joel Greenblatt) (%) -289.20
MNTA's ROC (Joel Greenblatt) (%) is ranked lower than
55% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -0.20 vs. MNTA: -289.20 )
MNTA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4241.7   Max: 372.2
Current: -289.2
-4241.7
372.2
Revenue Growth (%) 25.6
MNTA's Revenue Growth (%) is ranked higher than
98% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. MNTA: 25.6 )
MNTA' s 10-Year Revenue Growth (%) Range
Min: -9.3   Max: 92
Current: 25.6
-9.3
92
EBITDA Growth (%) -8.4
MNTA's EBITDA Growth (%) is ranked lower than
81% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -11.35 vs. MNTA: -8.4 )
MNTA' s 10-Year EBITDA Growth (%) Range
Min: -17.3   Max: 22.2
Current: -8.4
-17.3
22.2
EPS Growth (%) -7.7
MNTA's EPS Growth (%) is ranked lower than
52% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -8.70 vs. MNTA: -7.7 )
MNTA' s 10-Year EPS Growth (%) Range
Min: -24.6   Max: 21.8
Current: -7.7
-24.6
21.8
ยป MNTA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

MNTA Guru Trades in Q2 2012

Joel Greenblatt 156,057 sh (+502.05%)
PRIMECAP Management 1,039,556 sh (+56.99%)
John Burbank 150,000 sh (unchged)
Paul Tudor Jones Sold Out
Richard Snow Sold Out
Jim Simons 743,351 sh (-28.75%)
» More
Q3 2012

MNTA Guru Trades in Q3 2012

Jim Simons 868,751 sh (+16.87%)
Joel Greenblatt 173,864 sh (+11.41%)
PRIMECAP Management 1,048,600 sh (+0.87%)
John Burbank Sold Out
» More
Q4 2012

MNTA Guru Trades in Q4 2012

Paul Tudor Jones 20,500 sh (New)
Steven Cohen 49,200 sh (New)
PRIMECAP Management 1,141,200 sh (+8.83%)
Joel Greenblatt Sold Out
Jim Simons 788,751 sh (-9.21%)
» More
Q1 2013

MNTA Guru Trades in Q1 2013

PRIMECAP Management 1,341,200 sh (+17.53%)
Paul Tudor Jones Sold Out
Jim Simons 163,000 sh (-79.33%)
Steven Cohen 700 sh (-98.58%)
» More
» Details

Insider Trades

Latest Guru Trades with MNTA

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2012-12-31 Sold Out 0.17%$10.32 - $14.82 $ 13.086%0
John Burbank 2012-09-30 Sold Out 0.07%$13.48 - $15.03 $ 13.08-8%0
Joel Greenblatt 2012-06-30 Add 502.05%0.13%$13.13 - $16.24 $ 13.08-11%156057
PRIMECAP Management 2012-06-30 Add 56.99%0.01%$13.13 - $16.24 $ 13.08-11%1039556
John Burbank 2012-03-31 New Buy0.08%$14.48 - $19.58 $ 13.08-14%150000
Joel Greenblatt 2012-03-31 Add 62.29%0.01%$14.48 - $19.58 $ 13.08-14%25921
Joel Greenblatt 2011-09-30 New Buy0.04%$10.62 - $20.92 $ 13.08-22%19658
PRIMECAP Management 2011-06-30 Add 866.56%0.02%$15.26 - $20.01 $ 13.08-29%724922
PRIMECAP Management 2011-03-31 New Buy$12.485 - $17.1 $ 13.08-9%75000
Premium More recent guru trades are included for Premium Members only!!

Ratios

vs
industry		 vs
history
P/B 1.90
MNTA's P/B is ranked higher than
78% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. MNTA: 1.90 )
MNTA' s 10-Year P/B Range
Min: 1.31   Max: 14.69
Current: 1.9
1.31
14.69
P/S 13.97
MNTA's P/S is ranked lower than
52% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 6.90 vs. MNTA: 13.97 )
MNTA' s 10-Year P/S Range
Min: 1.84   Max: 60.6
Current: 13.97
1.84
60.6
EV-to-EBIT 6.4
MNTA's EV-to-EBIT is ranked higher than
83% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 14.61 vs. MNTA: 6.4 )
MNTA' s 10-Year EV-to-EBIT Range
Min: 1.3   Max: 17.4
Current: 6.4
1.3
17.4

Valuation & Return

vs
industry		 vs
history
Price/Net Cash 2.3
MNTA's Price/Net Cash is ranked higher than
70% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 8.80 vs. MNTA: 2.3 )
MNTA' s 10-Year Price/Net Cash Range
Min: 2   Max: 7.1
Current: 2.3
2
7.1
Price/Net Current Asset Value 46.7
MNTA's Price/Net Current Asset Value is ranked higher than
82% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 32.60 vs. MNTA: 46.7 )
MNTA' s 10-Year Price/Net Current Asset Value Range
Min: 14.1   Max: 96.9
Current: 46.7
14.1
96.9
Price/Tangible Book 1.9
MNTA's Price/Tangible Book is ranked higher than
50% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 4.70 vs. MNTA: 1.9 )
MNTA' s 10-Year Price/Tangible Book Range
Min: 1.7   Max: 5.5
Current: 1.9
1.7
5.5
Price/DCF (Projected) 2.1
MNTA's Price/DCF (Projected) is ranked higher than
92% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 2.00 vs. MNTA: 2.1 )
MNTA' s 10-Year Price/DCF (Projected) Range
Min: 1.8   Max: 3
Current: 2.1
1.8
3
Price/Median PS Value 0.7
MNTA's Price/Median PS Value is ranked higher than
54% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 0.90 vs. MNTA: 0.7 )
MNTA' s 10-Year Price/Median PS Value Range
Min: 0.1   Max: 2
Current: 0.7
0.1
2
Earnings Yield (Greenblatt) 15.60
MNTA's Earnings Yield (Greenblatt) is ranked higher than
86% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 8.00 vs. MNTA: 15.60 )
MNTA' s 10-Year Earnings Yield (Greenblatt) Range
Min: 5.7   Max: 77.8
Current: 15.6
5.7
77.8
Forward Rate of Return (Yacktman) 0.81
MNTA's Forward Rate of Return (Yacktman) is ranked higher than
99% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -4.65 vs. MNTA: 0.81 )
MNTA' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -11   Max: -2.5
Current: 0.81
-11
-2.5

Business Description

Momenta Pharmaceuticals, Inc. was incorporated in the state of Delaware in May 2001 and began operations in early 2002. The company is a biotechnology company specializing in the structural characterization, process engineering and biologic systems analysis of complex molecules, such as polysaccharides, polypeptides, and biologics (including proteins and antibodies). The company's generics and follow-on biologics effort is focused on building a thorough understanding of the structure-process-activity of complex mixture drugs to develop generic versions of marketed products. While Momenta uses a similar analytical and development approach across all of its product candidates, it tailors that approach for each specific product candidate. The company's first objective is to apply its core analytical technology to thoroughly characterize the structure of the marketed product.Momenta's two most advanced complex generic candidates target marketed products which were originally approved by the FDA as New Drug Applications. Therefore, it was able to access the existing regulatory pathway for generic product candidates and submit an Abbreviated New Drug Application for these generic candidates. M-Enoxaparin is designed to be a technology-enabled generic version of Lovenox, a low molecular weight heparin used to prevent and treat deep vein thrombosis and to support the treatment of acute coronary syndromes. This drug is a complex mixture of polysaccharide chains derived from naturally sourced heparin. The company's second major generic product candidate is M356, a technology-enabled generic version of Copaxone, a drug that is indicated for the reduction of the frequency of relapses in patients with Relapse-Remitting Multiple Sclerosis. Copaxone consists of a complex mixture of polypeptide chains. With M356, it has extended its core characterization capabilities from the characterization of complex polysaccharide mixtures to include the characterization of complex polypeptide mixtures. In addition to Momenta's two complex generic product candidates, which are both currently under review by FDA, it has further extended its analytical and development platform to pursue generic or follow-on versions of biologic drugs. The company's efforts on M178, as well as its ongoing Glycoprotein Research Program, are focused on developing generic or follow-on versions of marketed therapeutic proteins which are derived from natural or cell based manufacturing processes.
Company Website
SEC Reports
Industry: Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG
Traded in other countries:LZ1.Germany
ยป More Articles for MNTA

Headlines

Articles On GuruFocus.com
Very Low P/E Stocks Joel Greenblatt selected Dec 22 2011 
Momenta Pharmaceuticals Inc. (MNTA) SVP, CFO Richard P Shea sells 979 Shares Feb 24 2011 
Momenta Pharmaceuticals Inc. (MNTA) COO Stephen B Brugger sells 45,296 Shares Aug 05 2010 
Momenta Pharmaceuticals Inc. (MNTA) COO Stephen B Brugger sells 7,800 Shares Mar 12 2010 
Momenta Pharmaceuticals Inc. (MNTA) COO Stephen B Brugger sells 32,200 Shares Mar 10 2010 
Momenta Pharmaceuticals Inc. (MNTA) COO Stephen B Brugger sells 1,413 Shares Mar 03 2010 

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial